196 related articles for article (PubMed ID: 25170421)
1. Insights into the mechanism of C5aR inhibition by PMX53 via implicit solvent molecular dynamics simulations and docking.
Tamamis P; Kieslich CA; Nikiforovich GV; Woodruff TM; Morikis D; Archontis G
BMC Biophys; 2014; 7():5. PubMed ID: 25170421
[TBL] [Abstract][Full Text] [Related]
2. Structural complexes of the agonist, inverse agonist and antagonist bound C5a receptor: insights into pharmacology and signaling.
Rana S; Sahoo AR; Majhi BK
Mol Biosyst; 2016 Apr; 12(5):1586-99. PubMed ID: 26978009
[TBL] [Abstract][Full Text] [Related]
3. Orthosteric and allosteric action of the C5a receptor antagonists.
Liu H; Kim HR; Deepak RNVK; Wang L; Chung KY; Fan H; Wei Z; Zhang C
Nat Struct Mol Biol; 2018 Jun; 25(6):472-481. PubMed ID: 29867214
[TBL] [Abstract][Full Text] [Related]
4. Structural study of Ac-Phe-[Orn-Pro-dCha-Trp-Arg], a potent C5a receptor antagonist, by NMR.
Zhang L; Mallik B; Morikis D
Biopolymers; 2008; 90(6):803-15. PubMed ID: 18846566
[TBL] [Abstract][Full Text] [Related]
5. Comparative agonist/antagonist responses in mutant human C5a receptors define the ligand binding site.
Higginbottom A; Cain SA; Woodruff TM; Proctor LM; Madala PK; Tyndall JD; Taylor SM; Fairlie DP; Monk PN
J Biol Chem; 2005 May; 280(18):17831-40. PubMed ID: 15661745
[TBL] [Abstract][Full Text] [Related]
6. Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation.
Vergunst CE; Gerlag DM; Dinant H; Schulz L; Vinkenoog M; Smeets TJ; Sanders ME; Reedquist KA; Tak PP
Rheumatology (Oxford); 2007 Dec; 46(12):1773-8. PubMed ID: 17965442
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of inflammation and fibrosis by a complement C5a receptor antagonist in DOCA-salt hypertensive rats.
Iyer A; Woodruff TM; Wu MC; Stylianou C; Reid RC; Fairlie DP; Taylor SM; Brown L
J Cardiovasc Pharmacol; 2011 Nov; 58(5):479-86. PubMed ID: 21753735
[TBL] [Abstract][Full Text] [Related]
8. Modeling molecular mechanisms of binding of the anaphylatoxin C5a to the C5a receptor.
Nikiforovich GV; Marshall GR; Baranski TJ
Biochemistry; 2008 Mar; 47(10):3117-30. PubMed ID: 18275159
[TBL] [Abstract][Full Text] [Related]
9. Cleavage of the human C5A receptor by proteinases derived from Porphyromonas gingivalis: cleavage of leukocyte C5a receptor.
Jagels MA; Ember JA; Travis J; Potempa J; Pike R; Hugli TE
Adv Exp Med Biol; 1996; 389():155-64. PubMed ID: 8861006
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of the gerbil C5a receptor and identification of a transmembrane domain V amino acid that is crucial for small molecule antagonist interaction.
Waters SM; Brodbeck RM; Steflik J; Yu J; Baltazar C; Peck AE; Severance D; Zhang LY; Currie K; Chenard BL; Hutchison AJ; Maynard G; Krause JE
J Biol Chem; 2005 Dec; 280(49):40617-23. PubMed ID: 16230349
[TBL] [Abstract][Full Text] [Related]
11. Transdermal pharmacology of small molecule cyclic C5a antagonists.
Proctor LM; Woodruff TM; Sharma P; Shiels IA; Taylor SM
Adv Exp Med Biol; 2006; 586():329-45. PubMed ID: 16893082
[TBL] [Abstract][Full Text] [Related]
12. Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity.
March DR; Proctor LM; Stoermer MJ; Sbaglia R; Abbenante G; Reid RC; Woodruff TM; Wadi K; Paczkowski N; Tyndall JD; Taylor SM; Fairlie DP
Mol Pharmacol; 2004 Apr; 65(4):868-79. PubMed ID: 15044616
[TBL] [Abstract][Full Text] [Related]
13. Complement C5a is detrimental to histological and functional locomotor recovery after spinal cord injury in mice.
Li L; Xiong ZY; Qian ZM; Zhao TZ; Feng H; Hu S; Hu R; Ke Y; Lin J
Neurobiol Dis; 2014 Jun; 66():74-82. PubMed ID: 24607885
[TBL] [Abstract][Full Text] [Related]
14. Investigating the Dynamic Binding Behavior of PMX53 Cooperating with Allosteric Antagonist NDT9513727 to C5a Anaphylatoxin Chemotactic Receptor 1 through Gaussian Accelerated Molecular Dynamics and Free-Energy Perturbation Simulations.
Xiaoli A; Yuzhen N; Qiong Y; Yang L; Yao X; Bing Z
ACS Chem Neurosci; 2022 Dec; 13(23):3502-3511. PubMed ID: 36428153
[TBL] [Abstract][Full Text] [Related]
15. The Model Structures of the Complement Component 5a Receptor (C5aR) Bound to the Native and Engineered
Sahoo AR; Mishra R; Rana S
Sci Rep; 2018 Feb; 8(1):2955. PubMed ID: 29440703
[TBL] [Abstract][Full Text] [Related]
16. Model structures of inactive and peptide agonist bound C5aR: Insights into agonist binding, selectivity and activation.
Rana S; Sahoo AR
Biochem Biophys Rep; 2015 May; 1():85-96. PubMed ID: 29124137
[TBL] [Abstract][Full Text] [Related]
17. Emerging role of C5a/C5aR IL-17A axis in cGVHD.
Chen X; Lai P; Wang Y; He C; Wu S; Huang X; Geng S; Luo C; Ling W; Zeng L; Li P; Jiang Z; Weng J; Du X
Am J Transl Res; 2018; 10(7):2148-2157. PubMed ID: 30093951
[TBL] [Abstract][Full Text] [Related]
18. C5a receptor (CD88) promotes motility and invasiveness of gastric cancer by activating RhoA.
Kaida T; Nitta H; Kitano Y; Yamamura K; Arima K; Izumi D; Higashi T; Kurashige J; Imai K; Hayashi H; Iwatsuki M; Ishimoto T; Hashimoto D; Yamashita Y; Chikamoto A; Imanura T; Ishiko T; Beppu T; Baba H
Oncotarget; 2016 Dec; 7(51):84798-84809. PubMed ID: 27756879
[TBL] [Abstract][Full Text] [Related]
19. Attenuation of cGVHD by C5a/C5aR blockade is associated with increased frequency of Treg.
Wang Y; Lai P; Chen X; He C; Huang X; Geng S; Luo C; Wu S; Ling W; Zhong L; Lu Z; Li P; Weng J; Du X
Sci Rep; 2017 Jun; 7(1):3603. PubMed ID: 28620195
[TBL] [Abstract][Full Text] [Related]
20. Decoy nanoparticles bearing native C5a receptors as a new approach to inhibit complement-mediated neutrophil activation.
Li Y; Lin F
Acta Biomater; 2019 Nov; 99():330-338. PubMed ID: 31446047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
